The stock of Checkpoint Therapeutics Inc (CKPT) has seen a 60.73% increase in the past week, with a 18.51% gain in the past month, and a 1.02% flourish in the past quarter. The volatility ratio for the week is 1.26%, and the volatility levels for the past 30 days are at 5.69% for CKPT. The simple moving average for the past 20 days is 26.83% for CKPT’s stock, with a 40.50% simple moving average for the past 200 days.
Is It Worth Investing in Checkpoint Therapeutics Inc (NASDAQ: CKPT) Right Now?
Moreover, the 36-month beta value for CKPT is 1.16. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CKPT is 35.93M and currently, short sellers hold a 19.91% of that float. On March 17, 2025, CKPT’s average trading volume was 2.68M shares.
CKPT) stock’s latest price update
Checkpoint Therapeutics Inc (NASDAQ: CKPT)’s stock price has plunge by -0.50relation to previous closing price of 3.99. Nevertheless, the company has seen a 60.73% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-03-14 that NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone. KSF is seeking to determ.
Analysts’ Opinion of CKPT
Many brokerage firms have already submitted their reports for CKPT stocks, with D. Boral Capital repeating the rating for CKPT by listing it as a “Buy.” The predicted price for CKPT in the upcoming period, according to D. Boral Capital is $9 based on the research report published on January 13, 2025 of the current year 2025.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CKPT reach a price target of $7. The rating they have provided for CKPT stocks is “Buy” according to the report published on July 14th, 2022.
B. Riley Securities gave a rating of “Buy” to CKPT, setting the target price at $18 in the report published on June 09th of the previous year.
CKPT Trading at 25.07% from the 50-Day Moving Average
After a stumble in the market that brought CKPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.78% of loss for the given period.
Volatility was left at 5.69%, however, over the last 30 days, the volatility rate increased by 1.26%, as shares surge +14.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.51% upper at present.
During the last 5 trading sessions, CKPT rose by +60.73%, which changed the moving average for the period of 200-days by +115.76% in comparison to the 20-day moving average, which settled at $3.13. In addition, Checkpoint Therapeutics Inc saw 24.06% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CKPT starting from Oliviero James F III, who sale 10,331 shares at the price of $3.15 back on Feb 10 ’25. After this action, Oliviero James F III now owns 3,775,019 shares of Checkpoint Therapeutics Inc, valued at $32,543 using the latest closing price.
Oliviero James F III, the CEO, President and Director of Checkpoint Therapeutics Inc, sale 9,233 shares at $3.41 during a trade that took place back on Feb 07 ’25, which means that Oliviero James F III is holding 3,785,350 shares at $31,485 based on the most recent closing price.
Stock Fundamentals for CKPT
Current profitability levels for the company are sitting at:
- -798.17 for the present operating margin
- -451.68 for the gross margin
The net margin for Checkpoint Therapeutics Inc stands at -988.68. The total capital return value is set at 2.98.
Currently, EBITDA for the company is -52.15 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 3965.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.29.
Conclusion
To wrap up, the performance of Checkpoint Therapeutics Inc (CKPT) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
